VBI Vaccines has entered into a research collaboration with Sanofi Pasteur to apply VBI's LPV (Lipid Particle Vaccine) formulation technology to further the development of a key Sanofi Pasteur vaccine candidate.
Under the collaboration agreement, Sanofi Pasteur will leverage VBI's LPV technology and expertise to reformulate a Sanofi Pasteur vaccine candidate to provide improved stability.
Searching for more deal information? Current Partnering offers the following options:
|
The collaboration provides Sanofi Pasteur with the option to acquire certain worldwide rights to use VBI's LPV technology in its vaccines.
The vaccine candidate and the terms of the agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
